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Photodynamic therapy (PDT) is a recently developed treatment involving the use of a
photosensitizer and low power light, usually from a laser, to selectively destroy tumor
cells. At present, we perform PDT for head and neck cancer using argon or excimer dye
lasers with hematoporphyrin derivative as a photosensitizer. This study attempted to
assess the utility and safety of PDT and to investigate the long-term outcome. All 24
patients had squamous cell carcinoma: 15 with laryngeal, 5 with lingual or oral, and 4
with pharyngeal cancer and were treated by PDT. Data were obtained from records
from February 1988 through April 1995. After PDT, 12 of 15 laryngeal cancer patients
were classified as having a complete remission (CR), as were 2 ofthe 5 lingual or oral and
one of the 4 pharyngeal cancer patients. The patients were followed for 8 to 153 months.
The longest duration of CR in patients treated by PDT alone was 148 months.
Photosensitivity was experienced by all patients, but required no treatment. Liver, kid-
neys, and bone marrow showed no abnormal values. There were no clinically relevant
adverse reactions, and patients with severe complications due to other types oftreatment
and elderly patients were also treated safely with this therapy.
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INTRODUCTION
Since the early 1900s it has been known that photosen-
sitive substances can induce photochemical reactions
when exposed to light 1 ], and this phenomenon sug-
gested that a therapeutically beneficial photochemical
reaction can be induced in malignant tumors by tumor-
specific photosensitizers. Recently, attention has been
focused on photodynamic therapy (PDT) for cancer,
using tumor-specific photosensitizers and low-energy
laser light. Since Dougherty et al. [2] reported the first
application of PDT for cancer treatment in 1978, this
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procedure has become increasingly accepted, espe-
cially in lung cancer [3] and cervical carcinoma. It has
also been applied in patients with cancer of the stom-
ach, esophagus, and bladder. The widening of indica-
tions is related to the development of tumor-specific
photosensitizers, such as hematoporphyrin derivative
(HpD), which have low toxicity and mutagenicity but
good affinity to tumors and also the development of
low-energy laser light sources and endoscopes to trans-
mit laser light to target lesions. Concerning application
to head and neck cancer, several reports have been
published from the United States and Europe on laryn-
geal papilloma [4] recurrent tumor [5], and oral cancer,
while in Japan, there has only been one report on laryn-
geal carcinoma by Yoshida et al. [6]. We reviewed the
efficacy, safety, and long-term outcome of PDT in
patients with head and neck cancer.
APPLICATION OF PHOTODYNAMIC
THERAPY
Principle
When photosensitizers are excited by absorbing light
energy, a physicochemical reaction will occur by tran-
sition of energy state. In this reaction, the excited pho-
tosensitizers emit energy, activate oxygen in tissue,
and produce activated oxygen. Since activated oxygen
has cytotoxic effects, degeneration and destruction of
tissue cells may occur (Fig. 1).
Photosensitizers and Laser System
To obtain an adequate photodynamic effect, a
hematoporphyrin hydrochloride derivative, HpD, is
used as a photosensitizer because it has sufficient
affinity to tumors and low toxicity against normal tis-
sue [7,8]. Thus, selective therapy is capable by irradi-
ating the laser beam during the period when HpD is
accumulated in tumoral tissue [9]. The HpD can be
excited by relatively highly histopermeable red light
(630 nm) generated by an argon dye laser. However,
because the generated laser light is a continuous sinu-
soidal wave, the histopermeability and the amount of
photons are limited. To resolve this problem, an
excimer dye laser, which can generate a pulsed beam,
has been applied [10-12]. This device can generate a
peak output sufficiently high to produce a transient
high-density excitation state and improve the histop-
ermeability. We used two devices, an argon dye laser
and a excimer dye laser, for treatment of head and
neck cancers.
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SUBJECTS AND METHODS
Subjects
The subjects were 24 patients with squamous cell car-
cinoma who underwent PDT from February 1988
through April 1995. The mean age was 65 years
(range, 45 to 86 years). Of 15 patients with laryngeal
carcinoma, 13 patients underwent PDT as the first
treatment of choice (T la: 6 patients; T lb: 3 patients;
T2:3 patients; and T3:1 patient), and 2 patients were
treated for recurrence after radiotherapy. PDT was the
only possible choice in 2 patients with T2 cancer, 3
patients with T3 cancer who refused other therapeutic
modalities, and also in 2 patients with recurrence after
radiotherapy, one who refused total laryngectomy and
one who had synchronous combined cancer. PDT with
the argon dye laser was used for initial treatment in 3
patients and for treatment of recurrence in 1 patient,
and the excimer dye laser was applied for all other
patients. In all 5 lingual or oral cancer patients the
lesions were less than 4 cm in maximum dimension.
Four of the patients were treated by the argon dye
laser, while the last one was treated with an excimer
dye laser. In the 4 patients with pharyngeal carcinoma,
PDT was included in a multidisciplinary therapeutic
regimen in 2 patients and was performed for treatment
of locally recurrent lesions after chemotherapy and
radiotherapy in 1 patient (Table I). Informed consent
was obtained from all patients.
Methods
HpD (2.0 mg/kg) was administered intravenously 48
hr before the laser irradiation. In 5 patients (cases 1 to
4 and 14), laser light transmitted by a quartz fiber
(400 gm) was applied to the lesion under general
anesthesia during direct endoscopic observation.
TABLE PDT for Head and Neck Cancer
Case No. Age (yr) Sex T Laser:ErdJoule Effects ofPDT
Larynx
73 M Tla
2 69 M Tla
3 67 M Tla
4 66 M Tla
5 53 M Tla
6 68 M Tla
7 70 M Tlb
8 79 M Tlb
9 67 M Tlb
10 72 M T2
11 68 M T2
12 62 M T2
13 66 M T3
14 63 M rT1
15 45 M rT2
Lingual or oral
16 67 M T2
17 56 F T1
18 76 M T1
19 51 M T1
20 51 M T1
Pharynx
21 54 M T2
22 65 M T3
23 69 F rT2
24 86 M T3
Ex: 180
Ar:300;Ex: 150
Ar:1056
Ex:200;Ex: 100
Ex:100
Ex:200;Ex:200
Ex:200;Ex:200
Ex:200
Ex:200
Ar:500;Ar:500
Ex:650
Ex:200
Ex:200
Ar:810
Ar:800
Ar:500
At:300
Ar:300
Ar:500
Ex:200
Ar:450;Ar:300
Ar:500;Ar:1100
Ar:250
Ex:400
CR
CR
CR
CR
CR
CR
CR
PR
CR
PR
PR
CR
CR
CR
CR
PR
PR
PR
CR
CR
PR
PR
PR
CR
r, retreated patients; Ex, excimer; Ar, argon.44 T. YOSHIDA et al.
Other patients underwent a more sophisticated proce-
dure; i.e., under local anesthesia after insertion of a
videoendoscope, a quartz fiber was inserted via the
biopsy channel and PDT was performed. With the
argon dye laser (Fuji Photo Optical Co., Ltd.) 200 to
500 mW/cm2 was delivered by continuous wave laser
light for 20 min, while the excimer laser (Hamamatsu
Photonics Co.) delivered 3 to 4 mJ/pulse (30 Hz), 100
to 150 J/cm2 or 3 to 4 mJ/pulse (40 Hz), 200 J/cm2.
The energy dose was calculated according to the fol-
lowing equation;
En 200-500mW x irradiation time (sec)/cm2
(argon dye laser)
En (3-4 mJ/pulse x 30,40 or 80 Hz/sec)/1000 x
irradiation time (sec)/cm
2
(excimer dye laser)
We set the basic dose at an energy level of 200 J/cm2
(4 rnJ x 40 Hz x 60 sec x 21 min/1000 200 J/cm2
(Table II).
Since a long period of radiation was difficult under
local anesthesia due to occasional swallowing and
cough reflex, high dose irradiation using laser light
with 80 Hz was attempted to reduce the irradiation
time. However, this procedure does not seem to be
suitable for routine therapy because moderate flare
and swelling sometimes occur in the normal mucosa.
In the larynx, superficial irradiation is effective in can-
cers on the surface of the glottis, while quartz fibers
with perpendicular lens or a cylindrical quartz fibers
are required for cancers in the lower surface or border
of the larynx. In addition, photoradiation must be per-
formed with the tip of the transmitting fiber at a dis-
tance of 1 cm from the target surface to prevent the
defocus phenomenon in all cases.
RESULTS
Effects of Primary Therapy ofPDT
Among 13 patients with laryngeal cancer who under-
went PDT as the first treatment of choice; 1 patient
with Tlb and 2 patients with T2 resulted in partial
remission (PR), while the other 10 patients achieved
complete remission (CR), resulting in a CR rate of
76.9%. In 9 T1 patients, a CR was recognized in 8 and
a PR was recognized in 1 who refused repeated PDT.
In addition, 2 patients with T2 cancer who underwent
PDT for recurrent lesions initially treated by radio-
therapy regained a CR for as long as 5 and 13 months,
and 1 T3 patients also attained a CR. Consequently the
overall CR rate was 80.0%.
In 5 patients with lingual or oral squamous cell car-
cinoma, residual cancer was detected in all resected
specimens of the argon dye laser group except for
patient 19. In patient (case 20), the first patient to
undergo excimer dye laser irradiation for lingual can-
cer, a CR was obtained. The argon dye laser was used
in 4 patients with pharyngeal cancer, 2 ofwhom were
treated with PDT as par-t of a multidisciplinary regi-
men (cases 21 and 22) and 1 was treated for local
recurrence after chemotherapy and radiotherapy
(case 23). In all those patients a PR was achieved in
spite of manifestation of a severe cell necrotic reac-
tion. On the other hand a CR was achieved in 1
patient (case 24) with T3 cancer by excimer dye laser
irradiation alone.
TABLE II PDT Procedure
Intravenous injection of hematoporphyrin derivative (2.0 mg/kg)
48 hr before laser irradiation
Laser-power
Argon dye laser: continuous wave 200-500 mW/cm2
Excimer dye laser: pulse 3-4 mJ/P (30 Hz)
Optimal dose of laser energy: 200 J/cm
Optimal wave length: 630 nm
Effective Period and Long-Term Results ofPDT
The longest follow-up period was 153 months. The
first 2 patients were not evaluated because they
underwent prophylactic radiotherapy after 2 months.
In other patients with laryngeal carcinoma, a CR after
PDT alone was maintained for 148 months. In
patients treated with PDT as the initial treatment, all
cancers were locally controlled except for 1 patientPDT FOR HEAD AND NECK CANCER 45
(T1a) who underwent radiotherapy for local recurrent
cancer after 21 months. One patient (case 14) with a
T3 lesion of the larynx is at present disease-free after
44 months. All patients with recurrence after radio-
therapy had to undergo laryngectomy for cure. Our
single patient with recurrence after PDT was success-
fully treated by radiotherapy. The larynx preservation
rate was 85.7%, and in all patients who underwent
PDT as a primary therapy the larynx has been pre-
served. One patient with lingual and one with oral
cancer attained CR and are free of disease after 148
months. PDT was performed as one arm of multidis-
ciplinary therapy in most patients with pharyngeal
cancers, but a CR was obtained in only 1 lesion,
which did not recur for 15 months in spite of it having
been T3. Two patients treated for laryngeal cancer
died within 24 months from leukemia and esophageal
cancer, respectively. Our patient treated for lingual
cancer died from esophageal cancer. Two patients
with pharyngeal carcinoma died from their disease
(Table III).
Adverse Effects and Complications ofPDT
Skin photosensitization occurred in all patients, but no
specific treatment was required. Patients were advised
not to go out during the daytime, to avoid sunlight, and
to apply sunscreen cream for a few weeks after HpD
administration 13]. Laboratory test results indicated
that liver, kidneys, and bone marrow functions were
not affected by PDT. One patient with laryngeal carci-
noma underwent tracheotomy due to dyspnea caused
by laryngeal edema and glottic fur. In most patients
with laryngeal carcinoma, it was necessary to remove
fur endoscopically and perform tracheal lavage sev-
eral times. Severe edema occurred in patients with lin-
TABLE III Effective Period and Outcome ofPDT for Head and Neck Cancer
Case No. T Effective Period After Treatment Outcome
Larynx
Tla CR, 2 mo
2 Tla CR, 67 mo
3 Tla CR, 2 mo
4 Tla CR, 21 mo
5 Tla CR, 61 mo
6 Tla CR, 17 mo
7 Tlb CR, 17 mo
8 Tlb PR
9 Tlb CR, 8 mo
10 T2 PR
11 T2 PR
12 T2 CR, 8 mo
13 T3 CR, 44mo
14 rT1 CR, 5 mo
15 rT2 CR, 13 mo
Lingual or oral
16 T2 PR
17 T1 PR
18 T1 PR
19 T1 CR, 148 mo
20 T1 CR, 65mo
Pharynx
21 T2 PR
22 T3 PR
23 rT2 PR
24 T3 CR, 15 mo
Prophylactic irradiation
Prophylactic irradiation
Radiation for local recurrence
Radiation
Partial larnygectomy
Total laryngectomy
Total laryngectomy
Hemiglossectomy
Partial glossectomy
Partial glossectomy
Radiation
Radiation
Radiation
DOA, death of another; NED, no evidence of disease; DOD, death of disease.
DOA
NED
NED
NED
NED
NED
NED
NED
NED
NED
Unknown
NED
NED
NED
DOA
NED
NED
DOA
NED
NED
NED
DOD
DOD
NED46 T. YOSHIDA et al.
gual or oral cancer; however, most patients could eat
without any problem. In patient (case 24), however,
feeding via a nasogastric tube for 2 weeks was neces-
sary due to extensive erosive ulcers in the oral cavity.
Table I summarizes the results for all patients. The fol-
lowing case reports are representative.
Case 1
A patient with Tla laryngeal cancer was treated by
excimer dye laser radiation at 180 J/cm2 under general
anesthesia. Because this was the first patient and there
was a risk of dyspnea due to severe local reaction, the
patient underwent simultaneous prophylactic tra-
cheotomy. During this period, mucosal edema and accu-
mulation of necrotic tissue reduced the laryngeal lumen,
requiring frequent endoscopic removal of necrotic tis-
sue. Cytological diagnosis during the observation period
revealed Class III b cells although no recurrent cancer
was detected macroscopically; therefore, prophylactic
60 Gy Lineac irradiation was given. Figure 2 shows the
pretreatment appearance (upper) and appearance 4 days
after PDT (middle) and 4 months after PDT (lower).
The tracheostomy was closed after week, and no
recurrent cancer was detected for 24 months, but the
patient died of leukemia.
Case 7
In a patient with Tlb laryngeal cancer, PDT with an
excimer dye laser at 200 J/cm2 of energy was performed
twice under local anesthesia and observation by a
videoendoscope. Insufficient results were obtained by
the first PDT so a repeat procedure was performed (Fig.
3). No recurrence was observed after the second therapy.
Case 13
A patient with T3 laryngeal cancer who refused radio-
therapy or surgery was transferred to our hospital. Under
local anesthesia 200 J/cm2 from an excimer dye laser
was given under videoendoscopic observation. Although
we doubted the efficacy ofPDT in this T3 patient, a CR
was obtained after a singlePDT session, and no recurrent
cancer has occurred for 42 months (Fig. 4).
FIGURE 2 This patient (case 1) had Tla laryngeal cancer and was
treated by excimer dye laser radiation at 180 J/cm2 under general
anesthesia. Necrotic tissue was accumulated, and the laryngeal
mucosa became edematous. Prophylactic irradiation was performed
with 60 Gy of lineac electron radiation. Top, pretreatment view;
middle, 4 days after PDT; bottom, 4 months after PDT. No recurrent
cancer was detected for 24 months.PDT FOR HEAD AND NECK CANCER 47
FIGURE 3 This patient (case 7) suffered from Tlb laryngeal can-
cer and underwent PDT with an excimer dye laser at 200 J/cm
twice under local anesthesia, during observation by videoen-
doscopy. Top, pretreatment view; middle, 4 days after PDT; bottom
10 months after PDT.
FIGURE 4 This patient (case 10) suffered from T3 laryngeal can-
cer, but refused radiotherapy or surgery. Under local anesthesia, 200
J/cm of energy was radiated with an excimer dye laser. A CR was
attained by the first irradiation treatment, and no recurrence has
occurred at 42 months. Top, pretreatment view; middle, 4 days after
PDT; bottom, after 30 months.48 T. YOSHIDA et al.
Case I7
In a sublingual T1 cancer patient, the treated lesion
developed a furry surface after PDT probably due to a
severe necrotic reaction, but residual cancer cells were
detected in the resected specimen. However, this
patient is alive after 153 months without any other par-
ticular treatment (Fig. 5).
Case 24
An 86-year-old man had a T3 markedly elevated pha-
ryngeal tumor in the soft palate. PDT using an excimer
dye laser (4 mJ, 30 Hz, 400J/cm2) produced a CR,
which has been maintained for 15 months (Fig. 6).
FIGURE 5 This patient (case 17) suffered from sublingual T1
cancer. Although the treated lesion showed fur after PDT, probably
due to a severe necrotic reaction, residual cancer cells were detected
in the resected specimen. Top, pretreatment view; bottom, 2 weeks
after PDT.
FIGURE 6 This patient (case 24) suffered from T3 pharyngeal
cancer forming an extensive elevated tumor in the soft palate.
Considering the advanced age of the patient (86 years old), PDT
with a pulsed wave generated by an excimer dye laser (4 mJ, 30 Hz,
400 J/cm2) was selected. Top, pretreatment view; bottom, 10
months after PDT.PDT FOR HEAD AND NECK CANCER 49
DISCUSSION
Radiotherapy is an established treatment for cancer of
the head and neck and is used extensively in clinical
practice. Multidisciplinary therapy including chemo-
therapy and surgery has improved treatment outcome.
PDT has been reported to be effective as local therapy
for early stage cancers [14,15]. Kato et al. [14] and
Hayata et al. 16] have reported many clinical cases of
lung cancer on the basis of fundamental research.
Therefore, we attempted to use PDT for the treatment
of cancers of the head and neck. Although HpD itself
has no toxicity, photosensitization is an inevitable
complication, and there also have been reports of
recurrence after a CR was obtained by PDT 17]. We
found that the longest disease-free survival in early
stage laryngeal carcinoma by PDT alone was 67
months. In our study, cancer recurred in 1 patient
treated only by PDT after having been in CR for 21
months. However, other patients with lingual or oral
cancer and laryngeal carcinoma attained and main-
tained CR. The energy delivered by the argon dye laser
ranged from 300 to 1056 J/cm2. However, irradiation at
an energy level of 300 J/cm2 was not sufficient for
local control; thus additional laser irradiation was per-
formed in such patients. The energy of the excimer dye
laser ranged from 100 to 650 J/cm2, and local control
was obtained in 11 of 13 patients. Furthermore, in 2
patients with T3 disease, the tumor disappeared and did
not recur after irradiation of 200 to 400 J/cm2 using an
excimer dye laser. It was initially suspected that the
excimer dye laser might not be effective in large
advanced cancers; however, our results show that this
is not the case. Moreover, because the excimer dye
laser penetrates as deeply as 10 mm or more [18], it
may be useful in patients who refuse surgical resection
or whose general condition contraindicates surgery.
The fact that aCR was obtained in 9 of 10 patients with
T1 cancer in the larynx (including 1 patient with sec-
ondary PDT), and the single other patient, in which a
PR had been obtained, refused another PDT session,
suggests that PDT is comparable with conventional
treatments in terms of therapeutic effect.
Normal mucosa showed mild inflammation and
swelling immediately after PDT, the reaction reaching
a peak after 24 hr. Tumor tissue showed a more
intense reaction, forming fur and a crust, and some
patients with laryngeal carcinoma developed dyspnea
due to edema. Local reactions were especially intense
in the treated area in patients with early stage cancer in
whom maximum energy doses were given or areas
previously treated by another modality or PDT. Some
patients required daily endoscopic lavage, endoscopic
removal of secretions, or nebulizer-aided expectora-
tion. Although the patients with oral cancer mani-
fested severe edema in the oral cavity, none had
difficulty ingesting food, except 1 patient who had to
be fed via a nasogastric tube. Our animal experiments
and clinical experience established that energy expo-
sure should be 200 J/cm2 per PDT session, because at
this energy level the local reaction is not so marked as
to require complicated management or long-term
lavage. However, since the photoradiation must be
continued for 20 min even using a pulsed wave with 4
mJ, 40 Hz/pulse, it is necessary to maintain local anes-
thesia for at least that time.
The most important advantage of PDT is its ability
to target tumor selectively with minimal adverse
effects on other organs or surrounding tissue. PDT can
be completed in one or two sessions and can be
repeated if necessary. Another merit is the relative
lack of toxicity. HpD tends to be distributed in con-
nective tissue surrounding vessels. Since HpD accu-
mulates mainly in the cell membrane, cytoplasm, and
nuclear membrane, but not in the cell nuclei, it has no
mutagenicity or carcinogenicity; therefore, it can be
given safely to patients with severe complications or
elderly patients. Furthermore, PDT can be included in
multidisciplinary therapy and surgery or radiotherapy
can be performed after reduction of the tumor mass by
PDT. Palliative therapy of advanced cancer and local
treatment of recurrent cancer are also possible because
PDT does not prevent the application of other types of
treatment 19].
Several new laser generators have been developed
recently, such as the relatively inexpensive diode laser
and the tunable wavelength Nd-YAG OPO laser, and
they should be available commercially in the not too
distant future. On the other hand, it is necessar-y to
develop more effective and oncotropic photosensitiz-50 T. YOSHIDA et al.
ers. In addition to the currently used hematoporphyrin
derivative photosensitizer [20], several new photosen-
sitizers are under development with a view to improv-
ing therapeutic effect. These new substances include
chlorophylls, chlorides [ATX-S10 [21,22]], Chlorin-
e6 [NPe6 [23,24]], phthalocyanines [aluminum
phthalocyanine [25-27]], silicon phthalocyanine [28],
and pheophorbides (PH-1126), all of which are
excited by laser beams with longer wavelengths than
the light used with HpD so that histopermeability
might be improved.
SUMMARY
This report concerns the clinical course of 24 patients
with head and neck cancer who underwent PDT and
describes the efficacy, safety, and long-term results, as
well as improved PDT techniques under endoscopic
observation. The most important advantage ofPDT is
its ability to target malignant tissue selectively without
adverse effects on other organs and is safe enough to
apply even in elderly patients without risk of carcino-
genecity. There are some reports that with respect to
histologic findings, a CR is most likely to be achieved
in squamous cell carcinoma. For further progress in
the clinical practice ofPDT in head and neck cancer, it
is necessary to develop a laser beam that can penetrate
tissue more deeply. Although the number of patients
was limited, the long-term results appear equal or
superior to those of conventional procedures, suggest-
ing that PDT may be an effective strategy to treat can-
cer of the head and neck.
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